ReviewNeuropsychiatric disease and treatment2021
Current Perspectives on the Assessment and Management of Gait Disorders in Parkinson's Disease.
Review in Neuropsychiatric disease and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- External sensory cueing on gait in Parkinson's disease: a systematic review and network meta-analysis.Journal of neurology · 2026Pooled it
- Interventions to improve gait in Parkinson's disease: a systematic review of randomized controlled trials and network meta-analysis.Journal of neurology · 2022Pooled it
- Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Symptoms in Parkinson's Disease: Results from a Phase II Randomized Control Trial (STRIPE).Movement disorders : official journal of the Movement Disorder Society · 2025Trial
- Vertical locomotion improves horizontal locomotion: effects of climbing on gait and other mobility aspects in Parkinson's disease. A secondary analysis from a randomized controlled trial.Journal of neuroengineering and rehabilitation · 2024Trial
- A Smart Shoe System for Gait Analysis and Remote Monitoring in Parkinson's Disease-A Validation Study.Sensors (Basel, Switzerland) · 2026Article
- Dopamine and the dynamics of subthalamic and leg muscle activities in parkinsonian stepping.Brain : a journal of neurology · 2026Article
- Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy.Frontiers in pharmacology · 2026Review
- Hip exoskeleton assistance with machine-learning-based state estimation improves gait kinematics of people with Parkinson's disease.Frontiers in robotics and AI · 2026Article
- RecovGait: Occluded Parkinson's Disease Gait Reconstruction Using Unscented Tracking with Gated Initialization Technique.Sensors (Basel, Switzerland) · 2025Article
- Clinical Assessment of Walking Capacity in People With Parkinson Disease: Are 2 Minutes Sufficient?Physical therapy · 2025Article
- 80N as the Optimal Assistive Threshold for Wearable Exoskeleton-Mediated Gait Rehabilitation in Parkinson's Disease: A Prospective Biomarker Validation Study.Healthcare (Basel, Switzerland) · 2025Article
- Quantifying arm swing in Parkinson's disease: a method accounting for arm activities during free-living gait.Journal of neuroengineering and rehabilitation · 2025Article
- Machine learning for early detection and severity classification in people with Parkinson's disease.Scientific reports · 2025Article
- A Review of Recent Advances in Cognitive-Motor Dual-Tasking for Parkinson's Disease Rehabilitation.Sensors (Basel, Switzerland) · 2024Review
- Quality of life and living with Parkinson's disease: a qualitative exploration within an Irish context.BMC neurology · 2024Article
- Evaluating Gait Impairment in Parkinson's Disease from Instrumented Insole and IMU Sensor Data.Sensors (Basel, Switzerland) · 2023Article
- Analytical and clinical validity of wearable, multi-sensor technology for assessment of motor function in patients with Parkinson's disease in Japan.Scientific reports · 2023Article
- Compliance with National and International Guidelines in the Treatment of Nonmotor Symptoms in Late-Stage Parkinson's Disease.Parkinson's disease · 2023Article
- The implications of the foot health status in Parkinson patients: A case-control study.International wound journal · 2023Article
- High risk of developing dementia in Parkinson's disease: a Swedish registry-based study.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gait dysfunction is a key defining feature of Parkinson's disease (PD), and is associated with symptoms of freezing and an increased risk of falls. In this narrative review, we cover the putative mechanisms of gait dysfunction in PD, the assessment of gait abnormalities, and the management of symptoms caused by the inherent difficulty in walking. Our understanding of the causes of gait problems in PD has progressed in recent times, moving from neurocognitive theory to correlates of affected neuronal pathways. In particular, this can be shown to correspond with abnormalities in responses to dual-task paradigms and dysfunction in cholinergic signaling. Great progress has been made in the sophistication and precision of gait assessment; however, it has firmly remained in the research domain. There is significant momentum behind wearable technologies that can be used by patients in their own environment, acting as digital biomarkers that can not only reflect progression but also independently discriminate PD from non-PD individuals. The treatment of gait dysfunction has historically relied on physical therapies and training combined with a view to mitigating the impact of such consequences as falls. Pharmacological therapies that are the mainstay of treatment in PD have tended to address symptoms like bradykinesia; however, optimization of dopaminergic therapies likely has a positive effect on quality of gait. Other targets have been assessed with the goal of improving gait, of which medications that improve cholinergic signaling appear most promising. Neuromodulation techniques are increasingly used in the form of deep-brain stimulation; however, standard targets, such as the globus pallidus interna, have a modest effect on gait. Considerable benefit has been seen through targeting the pedunculopontine nucleus, and a dual-target approach may be warranted. Stimulation of the spinal cord and brain through direct or magnetic approaches has been assessed, but requires further evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.